BiotechTube

Atogepant

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Migraine Prophylaxis

Conditions

Migraine Prophylaxis

Trial Timeline

Jun 5, 2023 → Apr 1, 2032

NCT ID
NCT05707949

About Atogepant

Atogepant is a phase 3 stage product being developed by AbbVie for Migraine Prophylaxis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05707949. Target conditions include Migraine Prophylaxis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT06603558Pre-clinicalRecruiting
NCT05707949Phase 3Recruiting
NCT05216263Phase 3Completed

Competing Products

20 competing products in Migraine Prophylaxis

See all competitors
ProductCompanyStageHype Score
ABP-450AEON BiopharmaPhase 2
44
Lasmiditan + PlaceboEli LillyPhase 3
77
Placebo + LY2300559Eli LillyPhase 2
52
lasmiditan 200 mg + Sumatriptan + matching placeboEli LillyPhase 1
33
ABP-450 + PlaceboAEON BiopharmaPhase 2
44
Lasmiditan + PlaceboEli LillyPhase 2
52
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
44
Galcanezumab + ErenumabEli LillyApproved
85
Aricept (donepezil hydrochloride)EisaiPhase 2
52
E2007EisaiPhase 2
52
Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
85
Galcanezumab + PlaceboEli LillyPhase 3
77
Lasmiditan + PlaceboEli LillyPhase 2
52
Galcanezumab + PlaceboEli LillyPhase 3
77
LasmiditanEli LillyPhase 3
77
Galcanezumab Prefilled Syringe + PlaceboEli LillyPhase 2
52
Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved
85
GalcanezumabEli LillyPre-clinical
23
Galcanezumab + PlaceboEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 2
52

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85